LOWER AVERAGE SYSTOLIC PRESSURE (<140 MM HG) IS NOT ASSOCIATED WITH IMPROVED OUTCOMES IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY AGED 60 OR GREATER: FINDINGS IN SUPPORT OF THE JNC-8 RECOMMENDATIONS  by Okin, Peter M. et al.
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background:  JNC-8 recommends a target systolic pressure (SBP) <150 vs <140 in hypertensive patients aged 60 and older, but recent 
findings in hypertensive patients with coronary disease (CAD) found that average SBP <140 was associated with improved outcomes 
compared with SBP between 140 and 149 and SBP ≥150. Whether these findings are generalizable to hypertensive patients with ECG left 
ventricular hypertrophy (LVH) is unclear.
Methods:  Myocardial infarction (MI), stroke, incident heart failure (HF), cardiovascular (CV) and total mortality were examined in relation 
to average on-treatment SBP in 7154 hypertensive patients with ECG LVH ≥60 years old with baseline SBP ≥150 mm Hg randomized to 
losartan- vs atenolol-based treatment. Average on-treatment SBP 140 to 149 and average SBP ≥150 were compared with average SBP 
<140.
Results:  Compared with average SBP <140, average SBP 140 to 149 was associated with lower unadjusted outcome rates. In multiple 
propensity score adjusted Cox multivariate analyses, compared with average SBP <140, the risk of CV death, all-cause mortality and 
incident HF were all significantly lower in patients with average SBP of 140-149 and total mortality risk was also lower in the SBP ≥150 
group.
conclusion:  In contrast to hypertensive patients with CAD, in hypertensive patients with ECG LVH ≥60 years old, achieving an average 
on-treatment SBP target of 40 to 149 was associated with greater benefit than the previously recommended target of < 140.
Outcomes in Relation to Average On-Treatment Systolic Blood Pressure Achieved
Outcome
SBP <140
(n=1577)
SBP 140-149
(n=2378)
SBP ≥150
(n=3199)
Overall
p value*
Kaplan Meier Event Rates (per 1000 patient-years)
MI 10.3 8.0 10.8 0.072
Stroke 12.9 11.8 17.1 0.001
Incident HF 11.8 5.7 8.5 <0.001
CV Death 11.1 7.3 14.8 <0.001
All-cause 
mortality
23.3 14.7 25.2 <0.001
Multivariate Cox Models* (hazard ratios and 95% confidence intervals)
MI 1
0.80 (0.57-1.11, 
p=0.177)
0.98 (0.71-1.36, p=0.916) NA
Stroke 1
1.03 (0.77-1.37, 
p=0.871)
1.27 (0.96-1.69, p=0.100) NA
Incident HF 1
0.49 (0.34-0.71, 
p<0.001)
0.59 (0.42-0.82, p=0.002) NA
CV Death 1
0.68 (0.49-0.96, 
p=0.026)
1.21 (0.90-1.63, p=0.218) NA
All-cause 
mortality
1
0.68 (0.54-0.86, 
p=0.001)
1.03 (0.83-1.28, p=0.768) NA
*overall p value for Kaplan-Meier analyses; NA=not applicable
**adjusted for age, sex, race, randomized treatment, prior antihypertensive treatment, history of diabetes, MI, ischemic heart disease, heart failure, stroke, 
peripheral vascular disease, smoking, baseline serum glucose and creatinine, total and HDL cholesterol and propensity scores for likelihood of being in each SBP 
group as standard covariates, and for in-treatment heart rate, Sokolow-Lyon voltage and Cornell product LVH as time-dependent covariates
